🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Exclusive: Amplify Partners has raised $200 million for its first biotech-specific fund Targeting ~20 investments of $1.5m-$10m in pre-seed/seed/Series A-stage startups. The Silicon Valley VC has also hired Elliot Hershberg as a partner: endpoints.news/amplify-raises…

NEW: A trio of young MIT scientists say their new AI model has made progress in predicting binding affinity, a key property in drug discovery Good affinity prediction has evaded other AI models, but Boltz-2 showed solid improvement: endpoints.news/mit-scientists…

BREAKING: Resilience plans to wind down six under-utilized manufacturing sites — a reset in its ambitions of growing into a heavyweight in biopharma contracting: endpoints.news/national-resil…

NEW: Recursion is laying off 20% of its workforce, likely cutting over 150 jobs, Kyle LaHucik reports $RXRX cut its pipeline nearly in half last month, shelving five clinical- or near-clinical-stage programs endpoints.news/recursion-to-l…

I'm looking forward to breaking down this story with Dr. Cohen at 3:00pm ET. If you're looking for a primer on ACIP, and how its dismantling could affect the price and uptake of vaccines moving forward, tune in. We'll also address the broader message this sends to public health.

Here's a must-read deep dive into Bexorg, a biotech restoring dead human brains for better drug testing. A wild one from New Haven, CT from Ryan Cross the Science Boss: endpoints.news/rebooting-dead…

Basecamp CEO Glen Glowers on a "data wall" in AI bio: “We’ve effectively run out of the internet in biology ... BaseData represents the first example of being able to grow more internet, if you like, for biology.” endpoints.news/basecamp-resea…

12pm ET tomorrow — tune in for a Post-Hoc Live, where I'll be talking with Drew Armstrong and owl (in SF june 16th-27th) about how AI models think & work, and what that means for science (and the human scientists!) endpoints.news/endpoints-live…

during my unemployment, i have done many New Things, such as finishing half of The Sopranos and doing 2 V3’s in 24 hours, i will do another New Thing and chat live w/ the esteemed Andrew Dunn and Drew Armstrong yt link: youtube.com/live/S2AQ1mFhT…

Coming up at the top of the hour — tune in!

an enjoyable 40 minute chat i got a sudden sense of dread an hour before the interview, thinking it would be equivalent to a job interview, and that i would be asked to explain, live, why typical self attention doesn't work for alphafold2 MSA inputs. this did not happen

NEW: After spending its first year in relative quiet since its billion-dollar public debut, Xaira is out with its first preprint I talked with Xaira's lead scientist on the project, which includes releasing 8 million cells' worth of Perturb-seq: endpoints.news/ai-biotech-xai…

Join the Endpoints News team live from the BIO floor — we're talking conference takeaways, state of the biotech market, and more at 1:30p ET: youtube.com/watch?v=MGlDIc…

Exclusive: FDA's Makary sought rejection of KalVista’s drug in an unusual move by commissioner, sources say My latest — endpoints.news/sources-fda-ch…

If you work at the FDA, I am interested to hear more about your perspective. Please consider reaching out to me on Signal: my username is adunn123.30 endpoints.news/sources-fda-ch…

NEW: Some expert reaction & further context around FDA head Marty Makary's unsuccessful attempt to intervene in KalVista's drug review: endpoints.news/fda-head-makar…

NEW: The OpenAI-backed biotech startup Chai Discovery announced a new suite of AI models today, called Chai-2 The main result: making de novo antibodies with a 19% hit rate on average, which Zavain Dar called "fucking killer" endpoints.news/openai-backed-…

NEW: An inside look at the growing divide among US biotech investors over China's ascent Some VCs are capitalizing on China's rise by licensing in molecules and forming NewCo's. Others like Tweets from Zach Weinberg see a threat to the US biotech industry: endpoints.news/us-investors-d…

Despite delay, KalVista wins FDA approval after Makary's short-lived attempt to intervene endpoints.news/fda-approves-k…

NEW: I interviewed KalVista CEO Ben Palleiko on the heels of their FDA approval for its HAE drug. "We were fairly blindsided by when your report came out, because until then, we hadn’t had the slightest idea.” More here in my latest for Endpoints News: endpoints.news/kalvista-ceo-t…